丹红注射液联合瑞舒伐他汀治疗不稳定心绞痛的临床疗效

Clinical Effects of Danhong Injection and Rosuvastatin in the Treatment of Patients with Unstable Angina Pectoris

目的 :探讨丹红注射液联合瑞舒伐他汀治疗不稳定心绞痛的临床疗效。方法 :选择2015年8月-2016年10月我院收治的70例不稳定心绞痛患者为研究对象,按入院单双日分为观察组和对照组,对照组给予常规治疗,观察组给予丹红注射液(30 m L,qd)联合瑞舒伐他汀(5 mg,qd)治疗,比较两组的治疗效果。结果:观察组与对照组治疗后心绞痛症状评定与治疗前比较有统计学差异(P<0.05),且治疗后观察组心绞痛症状评定优于对照组(P<0.05);观察组总有效率为97.1%,高于对照组的82.8%(P<0.05);观察组与对照组治疗后肿瘤坏死因子(TNF)-α、超敏C反应蛋白(hs-CRP)和白细胞介素(IL)-6水平均低于治疗前(P<0.05),且观察组均低于对照组(P<0.05);治疗后两组血脂及血流动力学指标均改善,且观察组的改善均优于对照组(P<0.05)。结论 :采用丹红注射液与瑞舒伐他汀联合治疗不稳定心绞痛疗效显著,值得临床应用。

Objective:To investigate the clinical effects of danhong injection and rosuvastatin in the treatment of patients with unstable angina pectoris. Methods:70 cases of patients with unstable angina were selected from August 2015 to October 2016, and the patients were divided into observation group and control group. The control group was given routine treatment. The observation group was given danhong injection(30 m L, qd) combined with rosuvastatin(5 mg,qd). The therapeutic effect of the two groups was compared. Results:There was a statistical difference in symptoms of angina pectoris of the observation group and the control group after treatment compared with before treatment(P<0.05). After the treatment, the angina symptom evaluation in the observation group was significantly better than that in the control group(P<0.05). The total effective rate in observation group was 97.1% which was higher than 82.8% in control group(P<0.05). After one course of treatment, TNF-α, hs-CRP and IL-6 in observation group and control group were better than those before the treatment, and the indexes in observation group were lower than those in the control group. After treatment, the indexes of blood lipid and hemodynamics were improved in two groups, and the improvement of the observation group was better than that of the control group(P<0.05). Conclusion:The effect of danhong injection combined with rosuvastatin in the treatment of unstable angina pectoris is effective, and it is worthy of clinical application.